I-PARTS Integrated Platform for Anti-Cancer Radiation Therapeutics Screening

我们建议开发一个集成模块，用于癌症药物筛选中的高通量克隆细胞存活测定。I-PARTS，抗癌放射治疗筛选的综合平台结合了细胞培养自动化、微流体技术和高速图像分析的最新进展以及高通量X射线照射。在商业上，该产品还具有以高通量方式分析具有可变X射线剂量的各种癌症药物和不同细胞系的范围和可行性。允许细胞在具有体内模拟材料的三维环境中生长进一步促进了IPARTS模块在预测放射可治愈性的患者肿瘤样品克隆生成存活测定中被采用。实验验证和商业化将通过第二阶段SBIR提案进行。

We propose to develop an integrated module for high-throughput clonogenic cell survival assay in cancer drug screening. I-PARTS, Integrated platform for anti-cancer radiation therapeutics screening combines the recent advances in cell culture automation, microfluidics, and high-speed image analysis with the highthoughput X-ray irradiation. Commercially, the product also has the scope and feasibility to analyze various cancer drugs with variable X-ray doses, and different cell lines in a high-throughput manner. Allowing the cells to grown in the 3-dimensional environment with in vivo mimicking materials further facilitates the IPARTS module to be adopted in in patient tumor sample clonogenic survival assay predicting radiocurability. Experimental validation and commercialization will be pursued by a phase II SBIR proposal.